Comparison 1. Etrolizumab versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure to enter clinical remission at week 6	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.87, 1.06]
1.1 100 mg	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.82, 1.09]
1.2 300 mg	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.85, 1.11]
2 Failure to enter clinical remission at week 10 (Phase 1 study)	1	23	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.64, 1.69]
3 Failure to enter clinical remission at week 10	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.77, 0.95]
3.1 100 mg	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.68, 0.96]
3.2 300 mg	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.80, 1.03]
4 Failure to respond at week 6	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.64, 1.15]
4.1 100 mg	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.79 [0.51, 1.23]
4.2 300 mg	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.62, 1.36]
5 Failure to respond at week 10 (Phase 1 study)	1	23	Risk Ratio (M‐H, Fixed, 95% CI)	1.67 [0.26, 10.82]
6 Failure to respond at week 10	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.75, 1.23]
6.1 100 mg	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.66, 1.37]
6.2 300 mg	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.69, 1.36]
7 Failure to enter endoscopic remission at week 6	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.90, 1.06]
7.1 100 mg	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.83, 1.05]
7.2 300 mg	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.92, 1.14]
8 Failure to enter endoscopic remission at week 10	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.85, 1.00]
8.1 100 mg	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.80, 1.03]
8.2 300 mg	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.83, 1.05]
9 Adverse events	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
10 Serious adverse events	2	165	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.36, 2.34]
11 Withdrawal due to adverse events	2	165	Risk Ratio (M‐H, Fixed, 95% CI)	1.09 [0.26, 4.62]